FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

Using a more pragmatic classification system than the current standard provided clearer discrimination between disease ...

The largest US study to date on teen cannabis uses shows that cannabis use during adolescence may hinder cognitive improvement over time.

To have a drug that has an impact on mortality, it’s of huge interest and a benefit for patients with ILD,’ said rheumatologist Voon Ong, MBBS, PhD, who was not involved in the study.

Wheat allergy in young children is uncommon, but many referred children tolerate wheat protein or have a reaction only to ...

RFK Jr and Joe Rogan use them to heal, and NASA wants to put one in the astropharmacy. But without extensive data on humans, ...

The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.

Recent data from a single-arm trial suggest favorable-risk patients with HPV-associated oropharyngeal carcinoma may benefit from a deintensified regimen.

A study from a single medical center in California has observed a nearly 15% prevalence of methamphetamine use in patients presenting with acute coronary syndrome.

Risk-enhancing factors are highly prevalent in adults without atherosclerotic cardiovascular disease and strongly linked to statin use in those at high risk for the condition.